Atrial Natriuretic Peptide (ANP): Volume Reduction, Sodium Excretion & Pressure Offloading
Atrial natriuretic peptide (ANP) is a hormone released by the heart when blood volume and pressure become excessive. While the renin–angiotensin–aldosterone system (RAAS) and antidiuretic hormone (ADH) are designed to conserve sodium and water during low-volume states, ANP acts in direct opposition, functioning as the body’s built-in mechanism for relieving volume overload. Through its effects on the kidneys, blood vessels, and endocrine system, ANP promotes sodium excretion, water loss, vasodilation, and RAAS suppression. This helps protect the heart from overstretching and reduces the workload placed on the circulatory system.
What You Need to Know
Atrial natriuretic peptide (ANP) is a hormone released by cardiac atrial myocytes when they are stretched by increased blood volume or elevated venous return. This allows the heart to function as a volume sensor, detecting when the circulation is becoming overloaded. ANP acts as a physiological counterbalance to fluid-retaining systems such as the renin–angiotensin–aldosterone system, shifting the body toward volume and pressure reduction.
Once released, ANP produces coordinated renal, vascular, and hormonal effects that promote sodium and water loss:
increases glomerular filtration, allowing more sodium and water to be filtered
reduces sodium reabsorption in the renal tubules, enhancing natriuresis
causes systemic vasodilation, lowering peripheral resistance
suppresses renin, angiotensin II, aldosterone, and antidiuretic hormone
Together, these actions favour diuresis and a fall in circulating volume.
By linking atrial stretch to kidney function and vascular tone, ANP provides a rapid and protective mechanism to offload excess fluid before it causes sustained hypertension or cardiac stress. It allows the cardiovascular and renal systems to work together to maintain volume balance, blood pressure stability, and long-term circulatory health.
Beyond the Basics
Trigger for ANP Release: Atrial Stretch
The atria of the heart contain specialised mechanoreceptors that respond to changes in wall tension. When venous return increases, more blood enters the atria, stretching their walls. This occurs in states of hypervolaemia such as high salt intake, fluid overload, pregnancy, or heart failure, where circulating volume exceeds what the heart can comfortably handle. The mechanical deformation of atrial myocytes directly stimulates the release of stored atrial natriuretic peptide into the bloodstream.
This mechanism allows the heart to act as a volume sensor. Rather than responding to blood pressure alone, ANP release reflects how full the heart is. In this way, ANP functions as a counter-regulatory hormone that is activated specifically when the cardiovascular system is under strain from excess preload, signalling the kidneys and blood vessels to reduce circulating volume.
Renal Vasodilation & Increased GFR
One of the most powerful effects of ANP occurs within the kidney’s microcirculation. ANP causes dilation of the afferent arteriole, increasing blood flow into the glomerulus, while simultaneously constricting the efferent arteriole, which slows blood leaving the glomerulus. Together, these changes raise glomerular capillary pressure and significantly increase the glomerular filtration rate.
A higher GFR means that more sodium and water are filtered into the nephron, increasing the amount available for excretion. This mechanism allows the kidneys to rapidly eliminate excess volume when the circulation is overloaded. In contrast to angiotensin II, which preserves filtration during low blood pressure, ANP enhances filtration specifically when blood volume and venous return are excessive, helping to offload the heart.
Inhibition of Sodium Reabsorption
ANP not only increases how much fluid is filtered but also reduces how much sodium is reclaimed by the nephron. It acts primarily on the distal convoluted tubule and collecting ducts, where final sodium handling occurs, by altering the activity of key transport proteins. This includes reducing the function of epithelial sodium channels and the sodium–potassium pump, as well as modifying the medullary osmotic environment that normally promotes sodium and water reabsorption.
By impairing sodium reabsorption at these sites, ANP promotes natriuresis. Because water follows sodium osmotically, this also leads to increased urine volume. Unlike aldosterone, which conserves sodium to support blood volume, ANP actively promotes sodium elimination, shifting the kidney into a fluid-excreting state.
Suppression of RAAS Activity
ANP exerts strong inhibitory effects on the renin–angiotensin–aldosterone system, directly opposing one of the body’s main fluid-retaining pathways. It suppresses renin release from juxtaglomerular cells, which reduces the formation of angiotensin II, and it directly inhibits aldosterone secretion from the adrenal cortex. This prevents vasoconstriction, sodium retention, and long-term volume expansion.
By turning down RAAS activity, ANP prevents the kidneys from responding to volume overload with further sodium and water retention. This negative feedback protects the heart from persistently elevated filling pressures and helps stabilise circulation when fluid levels are high.
Inhibition of ADH Release & Action
ANP also suppresses antidiuretic hormone release and reduces the sensitivity of the collecting ducts to ADH. This decreases the insertion of aquaporin channels into the tubular membrane, limiting water reabsorption. As a result, more water remains in the tubular fluid and is excreted as urine.
This effect ensures that ANP not only removes sodium but also actively promotes free water loss, reinforcing its role as a volume-reducing hormone. Together with RAAS inhibition, this creates a coordinated shift away from fluid conservation.
Systemic Vasodilation
Beyond the kidneys, ANP produces widespread vasodilation in both arteries and veins. Arterial dilation lowers systemic vascular resistance, reducing blood pressure, while venous dilation decreases venous return to the heart. This directly reduces cardiac preload and relieves atrial stretch.
Because atrial stretch is the original trigger for ANP release, this forms a self-limiting feedback loop: as ANP reduces volume and pressure, atrial tension falls, and ANP secretion decreases. This elegant control system allows the heart and kidneys to work together to maintain circulatory stability when volume becomes excessive.
Clinical Connections
ANP plays a critical role in protecting the circulation from excessive fluid accumulation. In states of volume overload such as heart failure, cirrhosis, chronic kidney disease, and high-salt diets, atrial stretch increases ANP release as a compensatory attempt to promote sodium and water excretion and reduce cardiac filling pressures. In early disease this mechanism helps limit oedema and venous congestion, but in advanced heart failure the kidneys become resistant to natriuretic peptides, leading to persistent sodium retention despite high circulating ANP and BNP levels.
This resistance explains why patients with severe heart failure often continue to retain fluid even when ANP and BNP are markedly elevated. The kidneys fail to increase sodium excretion, and RAAS activity remains dominant, producing:
ongoing sodium and water retention
rising venous pressures and oedema
progressive cardiac and renal strain
The result is a vicious cycle of volume overload and worsening heart failure.
In contrast, when circulating volume is low, such as in dehydration, haemorrhage, or adrenal insufficiency, ANP levels fall. This removes the natriuretic signal to the kidneys, allowing sodium and water to be conserved in order to preserve circulating volume and maintain blood pressure. In these settings, low ANP supports survival by preventing unnecessary fluid loss.
Drugs that enhance natriuretic peptide activity are used in heart failure to counteract excessive RAAS-driven sodium retention. These agents increase natriuresis, promote diuresis, and reduce cardiac preload, helping relieve congestion and improve haemodynamics.
ANP also has an important clinical counterpart in B-type natriuretic peptide (BNP), which is released primarily from ventricular myocytes when the ventricles are overstretched. Because BNP rises in proportion to ventricular wall stress, it is widely used as a biomarker for diagnosing and monitoring heart failure. Elevated BNP levels reflect increased intracardiac pressure and volume overload, making it a useful indicator of disease severity.
Although BNP and ANP originate from different chambers of the heart, their physiological actions are closely aligned. Both promote sodium and water excretion, suppress RAAS activity, and cause vasodilation, reinforcing the body’s attempt to reduce volume and pressure when the heart is under strain.
Concept Check
Why does atrial stretch stimulate ANP release, and what problem is the body trying to correct?
How does ANP simultaneously increase GFR and promote sodium loss?
Why does ANP oppose the actions of renin, angiotensin II, aldosterone, and ADH?
Why does high ANP not always lead to natriuresis in advanced heart failure?
How does ANP help protect the heart during periods of fluid overload?